Thromboelastography Identifies Hypercoagulablilty and Predicts Thromboembolic Complications in Patients with Prostate Cancer

• Published in: Thrombosis research Vol. 133; no. 1; pp. 88 - 95
• Main Authors: Toukh, Mazen, Siemens, D. Robert, Black, Angela, Robb, Sylvia, Leveridge, Michael, Graham, Charles H, Othman, Maha
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01.01.2014
• Subjects: Aged; Aged, 80 and over; Cancer and VTE; Case-Control Studies; Hematology, Oncology and Palliative Medicine; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Pro-coagulant microparticles; Prostatic Neoplasms - blood; Prostatic Neoplasms - pathology; Prostatic Neoplasms, Castration-Resistant - blood; Prostatic Neoplasms, Castration-Resistant - pathology; Risk Factors; TEG; Thrombelastography - methods; Thromboembolism - blood; Thromboembolism - etiology; Thromboembolism - pathology; Thrombophilia - blood; Thrombophilia - etiology; Thrombophilia - pathology; Tissue factor; Pro-coagulant microparticles; Cancer and VTE; TEG; Tissue factor
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2013.10.007

Abstract Cancer patients are at higher risk for thromboembolism compared to the normal population. This may be related to tumour burden and/or enhanced by systemic therapy. While there is ample evidence regarding venous thromboembolism, systematic studies investigating arterial thrombotic events are scarce. Conventional coagulation tests have limited capacity in evaluating the coagulability or the need for anticoagulant prophylaxis. In this pilot study, we investigated whether assessment of global haemostasis using thromboelastography (TEG) and quantification of plasma pro-coagulant microparticles can help determine the risk of adverse thrombotic events in patients with prostate cancer (PCa). Thirty two patients were recruited a priori into three groups: 11 men on 'watchful waiting' following recurrent disease after definitive treatment (Group A); 10 patients with metastatic disease on Androgen deprivation therapy (ADT) (Group B); and 11 with castration resistant cancer (Group C) and followed up over a period of 12 months. These patients were compared to a control group composed of 8 men with negative prostate biopsy. Whole blood TEG and plasma tissue factor-carrying microparticles (TF-MPs) in addition to basic coagulation testing, plasma fibrinogen and d-dimer were performed. 22/32 (68.8%) of the patients demonstrated hypercoagulable TEG traces. Hypercoagulability was marked in group B compared to the control. Plasma MPs were significantly elevated in patients compared to the controls with significant increase in group B. All other coagulation tests were normal. Seven of the 22 hypercoagulable patients (31.8%) developed one or more thromboembolic events over 12 months follow up period. The data in this pilot study show that PCa patients are hypercoagulable, particularly those with advanced disease on ADT and that this hypercoagulability can be identified by TEG. While this needs to be verified in a larger study, the data indicate TEG may aid in thrombosis risk stratification and determining the subsequent need for anticoagulant prophylaxis in PCa patients.